Allgemeines
HD 8
HD 7
HD 6
HD 5
HD 4
HD - R3
HD - R2
PVAG 14
CCG 5942
JNJ40346527HKL1001
EORTC 20884 (14)
EORTC H10
ECHELON-1
RAPID
Quellen
Combined-modality therapy for clinical stage I or II Hodgkin’s lymphoma: Long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
JCO 24(2006):3128-3135
2.) Ferme C, et al.:
Four ABVD and involved-field radiotherapy in unfavorable supradiaphragmatic clinical stages (CS) I-II Hodgkin’s lymphoma (HL): Preliminary results of the EORTC-GELA H9-U trial.
Blood 106, 2005 (abstr 813)
3.) Diehl V:
Therapie des Morbus Hodgkin: Erfahrungen der Deutschen Hodgkin-Studiengruppe über vier Studiengenerationen.
Dtsch Arztebl 2002; 99(25): A 1760.
4.) Klimm B, Diehl V, Pfistner B, Engert A:
Current treatment strategies of the German Hodgkin Study Group (GHSG).
Eur J Haematol Suppl 2005; 66: 125–34.
5.) Dühmke E, Franklin J, Pfreundschuh M, et al.:
Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin’s disease: long-term results of a randomized trial of radiotherapy alone.
J Clin Oncol 2001; 19: 2905–14.
6.) Sieber M, Tesch H, Pfistner B, et al.:
Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin’s lymphoma: final results of the German Hodgkin’s Lymphoma Study Group Trial HD5.
J Clin Oncol 2002; 20: 476–84.
7.) Sieber M, Tesch H, Pfistner B, et al.:
Treatment of advanced Hodgkin’s disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin’s Lymphoma Study Group HD6 trial.
Ann Oncol 2004; 15: 276–82.
8.) Engert A, Franklin J, Eich HT, et al.:
Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: final results of the GHSG HD7 trial.
J Clin Oncol 2007; 25: 3495–502.
9.) Engert A, Schiller P, Josting A, et al.:
Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s Lymphoma: Results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group.
J Clin Oncol 2003; 21: 3601–8.
10.) Diehl V, Franklin J, Pfreundschuh M, et al.:
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease.
N Engl J Med 2003; 348: 2386–95.
11.) Engert A, Pluetschow A, Eich HT, et al.:
Reduced treatment intensity in patients with early-stage Hodgkin’s Lymphoma.
N Engl J Med 2010; 363: 640–52
12.) Eich HT, Diehl V, Görgen H, et al.:
Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
J Clin Oncol 2010; 28: 4199–206.
13.) Borchmann P, Haverkamp H, Diehl V, et al.:
Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin’s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group.
J Clin Oncol 2011; 29: 4234–42.
14.) Aleman BM, et al.:
Quality control of involved-field radiotherapy in patients with advanced Hodgkin’s lymphoma (EORTC 20884).
Int J Radiat Oncol Biol Phys 63(2005):1184–1190
